Long-term oral enoximone therapy in chronic cardiac failure
- 14 August 1987
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 60 (5), 63-67
- https://doi.org/10.1016/0002-9149(87)90528-5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Physiologic response to the inotropic and vasodilator properties of enoximoneThe American Journal of Cardiology, 1987
- Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathyThe American Journal of Cardiology, 1986
- Effects of a new cardiotonic agent, MDL-17,043, on myocardial contractility and left ventricular performance in congestive heart failureAmerican Heart Journal, 1985
- MDL 17,043: Short- and long-term cardiopulmonary and clinical effects in patients with heart failureJournal of the American College of Cardiology, 1985
- Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patientsJournal of the American College of Cardiology, 1984
- Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failureThe American Journal of Cardiology, 1984
- Characterization of the Cardiovascular Activities of a New Cardiotonic Agent, MDL 17043 (1,3-Dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one)Journal of Cardiovascular Pharmacology, 1982
- Oxygen utilization and ventilation during exercise in patients with chronic cardiac failure.Circulation, 1982
- Cardiovascular Properties of a New Cardiotonic AgentJournal of Cardiovascular Pharmacology, 1982
- Long-Term Vasodilator Therapy with Trimazosin in Chronic Cardiac FailureNew England Journal of Medicine, 1980